MedDRA preferred term · loss of taste

Ageusia: adverse event reports recording this term

24,631 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

24,631
reports recording the term: 0.1% of all reports; 1,217
reports, 12 months to June 2026: 1,334 in the 12 months before; 45.4%
marked serious by the reporter: 57.4% across all reports; 1.7%
record death among outcomes, as reported: 9.1% across all reports

"Ageusia" (in plain words, loss of taste) is a MedDRA preferred term recorded in 24,631 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,217 reports recorded it in the 12 months to June 2026, close to the 1,334 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 45.4% are marked serious, 1.7% include death among the outcomes and 12.5% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Revlimid, Erivedge and All Zicam Products. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Revlimid	Thalidomide analog	1,469	0.4%
Erivedge	Hedgehog pathway inhibitor	995	12.7%
All Zicam Products	—	706	92.4%
Zicam Cold Remedy	—	647	56.9%
Sutent	Kinase inhibitor	609	1.8%
Cabometyx	Kinase inhibitor	587	1.4%
Paxlovid	—	358	0.7%
Dupixent	Interleukin-4 receptor alpha antagonist	355	0.1%
Tiotropium bromide	Anticholinergic	318	0.4%
Zicam	Non-Standardized food allergenic extract	312	37%
Humira	—	301	0%
Terbinafine	Allylamine antifungal	268	6%
Zicam Cold Remedy Gel Swabs	—	261	50.9%
Ibrance	Kinase inhibitor	259	0.3%
Cosentyx	Interleukin-17A antagonist	253	0.2%
Votrient	Kinase inhibitor	216	1%
Ofev	Kinase inhibitor	211	0.9%
Esbriet	Pyridone	206	0.6%
Flonase	Corticosteroid	202	2.2%
Xtandi	Androgen receptor inhibitor	202	0.5%
Lamisil	—	200	4.7%
Chantix	Partial cholinergic nicotinic agonist	170	0.2%
Zicam Cold Remedy Rapidmelts	—	152	56.9%
Kisqali	Kinase inhibitor	144	0.6%
Afinitor	Kinase inhibitor	138	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Kinase inhibitor	3,103	0.4%	0.1%
Thalidomide analog	1,741	0.3%	0.2%
Corticosteroid	1,152	0.1%	0%
Hedgehog pathway inhibitor	1,057	10.9%	4.8%
Anticholinergic	452	0.3%	0.1%
GLP-1 receptor agonist	374	0.1%	0%
Interleukin-4 receptor alpha antagonist	374	0.1%	0.1%
Allylamine antifungal	322	6.3%	7.2%
Tumor necrosis factor blocker	320	0%	0%
Non-Standardized food allergenic extract	315	13.5%	0.5%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20%10

2 to 110.1%25

12 to 170.2%46

18 to 448.9%2,184

45 to 6422.9%5,646

65 to 7415.1%3,721

75 and over12.1%2,973

Age not given40.7%10,026

Patient sex

Female54.2%13,361

Male38.4%9,462

Not given7.3%1,808

Grey bar: all 20,646,523 reports in the database. 76.7% of these reports give the United States as the country.

Questions about "Ageusia"

What does "Ageusia" mean in an adverse event report?

In plain language: loss of taste. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record ageusia?

24,631 reports through June 2026 (0.1% of all reports), 1,217 of them in the latest 12 months.

Which drugs appear most often in these reports?

Revlimid (1,469), Erivedge (995), All Zicam Products (706), Zicam Cold Remedy (647) and Sutent (609). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.